We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target

Video   Jul 03, 2015

 



About the Speaker
Dr. Nils Hansen is the CEO and founder of Vipergen ApS. He is the principal inventor of the enabling YoctoReactor® and Binder Trap Enrichment® drug discovery technology platforms. He previously worked for Praecis Pharmaceuticals Inc., (Waltham, MA, USA) and Symphogen A/S, (Copenhagen, Denmark). Dr. Hansen earned his Ph.D. in immunology from the University of Copenhagen, Denmark in 2000 and his M.Sc. in Chemistry and Biotechnology from the University of Aarhus, Denmark in 1996.Abstract
Effective small molecule PPI blocker discovery using high fidelity DNA-encoded libraries and a low-noise homogeneous screening assay. The screen employs a unique principle of trapping small molecule binders together with the protein target in miniscule droplets.

 
 
 
 

Recommended Videos

Operetta CLS High-Content Analysis System

Video

The Operetta CLS system is part of PerkinElmer's comprehensive HCS portfolio – from HCS systems and microplates to automation and informatics.

WATCH NOW

In Pursuit of a Universal Antivenom

Video

When it comes to venomous snake bites, time is of the essence.
Find out how researchers are working to find an effective and affordable universal antivenom.

WATCH NOW

ULTImate YChemH: a powerful tool for drug target deconvolution

Video

What if I told you Hybrigenics Services can help you make the right decisions and optimize the success rate of your drug discovery and development programs?
Watch how with our animation video and discover our optimized ULTImate YChemH technology for drug target deconvolution.

WATCH NOW

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE